The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves’ disease

References

• Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375(16):1–7. doi: 10.1056/NEJMra1510030.
   PubMed Web of Science ®Google Scholar
• Smith MJ, Rihanek M, Coleman BM, et al. Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients. J Autoimmun. 2018;89:82–89. doi: 10.1016/j.jaut.2017.12.001.
   PubMed Web of Science ®Google Scholar
• Nargis T, Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB Life. 2018;70(2):112–119. doi: 10.1002/iub.1709.
   PubMed Web of Science ®Google Scholar
• Ansorge S, Nordhoff K, Bank U, et al. Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem. 2011;392(3):153–168. doi: 10.1515/BC.2011.008.
   PubMed Web of Science ®Google Scholar
• Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci. 2005;108(4):277–292. doi: 10.1042/CS20040302.
   PubMed Web of Science ®Google Scholar
• Varga T, Somogyi A, Barna G, et al. Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. Pathol Oncol Res. 2011;17(4):925–930. doi: 10.1007/s12253-011-9404-9.
   PubMed Web of Science ®Google Scholar
• Tejera-Alhambra M, Casrouge A, de Andres C, et al. Low DPP4 expression and activity in multiple sclerosis. Clin Immunol. 2014;150(2):170–183. doi: 10.1016/j.clim.2013.11.011.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Elia G, et al. Novel therapies for thyroid autoimmune diseases: an update. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101366. doi: 10.1016/j.beem.2019.101366.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang Y, Liu S, et al. CD26/DPP4 levels in peripheral blood and T cells in Hashimoto’s thyroiditis with normal thyroid function. Int Immunopharmacol. 2019;77:105941. doi: 10.1016/j.intimp.2019.105941.
   PubMed Web of Science ®Google Scholar
• Xu W, Liu Y, Cheng X, et al. Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto’s thyroiditis. Int Immunopharmacol. 2020;81:106315. doi: 10.1016/j.intimp.2020.106315.
   PubMed Web of Science ®Google Scholar
• Draznin B, Aroda VR, Bakris G, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–S43.
   PubMedGoogle Scholar
• Sekizaki T, Kameda H, Nomoto H, et al. Dipeptidyl peptidase-4 inhibitor might exacerbate Graves’ disease: a multicenter observational case-control study. J Diabetes Investig. 2021;12(11):1978–1982. doi: 10.1111/jdi.13578.
   PubMed Web of Science ®Google Scholar
• Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. doi: 10.1089/thy.2016.0229.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi: 10.1007/BF00280883.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fu Y, Yang Y, et al. Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease. J Int Med Res. 2022;50(7):3000605221112031. doi: 10.1177/03000605221112031.
   Web of Science ®Google Scholar
• Rohmann N, Schlicht K, Geisler C, et al. Circulating sDPP-4 is increased in obesity and insulin resistance but is not related to systemic metabolic inflammation. J Clin Endocrinol Metab. 2021;106(2):e592–e601. doi: 10.1210/clinem/dgaa758.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shao Y, Zhang H, et al. Comprehensive analysis of key genes and pathways for biological and clinical implications in thyroid-associated ophthalmopathy. BMC Genomics. 2022;23(1):630. doi: 10.1186/s12864-022-08854-5.
   PubMed Web of Science ®Google Scholar
• Piantanida E, Ippolito S, Gallo D, et al. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest. 2020;43(7):885–899. doi: 10.1007/s40618-020-01208-6.
   PubMed Web of Science ®Google Scholar
• LiVolsi VA, Baloch ZW. The pathology of hyperthyroidism. Front Endocrinol. 2018;9:737. doi: 10.3389/fendo.2018.00737.
   PubMed Web of Science ®Google Scholar
• Armengol MP, Juan M, Lucas-Martin A, et al. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol. 2001;159(3):861–873. doi: 10.1016/S0002-9440(10)61762-2.
   PubMed Web of Science ®Google Scholar
• Weetman AP, McGregor AM, Wheeler MH, et al. Extrathyroidal sites of autoantibody synthesis in Graves’ disease. Clin Exp Immunol. 1984;56(2):330–336.
   PubMed Web of Science ®Google Scholar
• Casrouge A, Sauer AV, Barreira da Silva R, et al. Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. Clin Exp Immunol. 2018;194(2):166–179. doi: 10.1111/cei.13163.
   PubMed Web of Science ®Google Scholar
• Zhao Y. CD26 in autoimmune diseases: the other side of ‘moonlight protein’. Int Immunopharmacol. 2019;75:105757. doi: 10.1016/j.intimp.2019.105757.
   PubMed Web of Science ®Google Scholar
• Hosono O, Ohnuma K, Dang NH, et al. CD26: a key molecule in immune regulation and autoimmune diseases. Mod Rheumatol. 2003;13(3):199–204. doi: 10.3109/s10165-003-0224-y.
   PubMedGoogle Scholar
• Abrahami D, Douros A, Yin H, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018;360:k872. doi: 10.1136/bmj.k872.
   PubMed Web of Science ®Google Scholar
• Kridin K, Amber K, Khamaisi M, et al. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol Res. 2018;66(3):425–430. doi: 10.1007/s12026-018-9005-8.
   PubMed Web of Science ®Google Scholar
• Preller V, Gerber A, Wrenger S, et al. TGF-beta1-mediated control of Central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol. 2007;178(7):4632–4640. doi: 10.4049/jimmunol.178.7.4632.
   PubMed Web of Science ®Google Scholar
• He X, Li W, Xie Y, et al. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1beta and IL-12 in NOD mice. Int Immunopharmacol. 2020;88:106945. doi: 10.1016/j.intimp.2020.106945.
   PubMed Web of Science ®Google Scholar